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To: Academic Year Undergraduate Research Initiative Committee  
Pepperdine University 
24255 Pacific Coast Hwy 
Malibu, CA 90263 
From: Kali Jelen 
24255 Pacific Coast Hwy #1727 
Malibu, CA 90264 
Re: Pepperdine Academic Year Undergraduate Research Initiative Submission 
 
December 11, 2015 
 
Dear Members of the Academic Year Undergraduate Research Committee, 
 
 I would like to preface my project with a brief explanation as well as to say thank you to 
several individuals. First and foremost thank you to Pepperdine University for encouraging 
undergraduate research through the Academic Year Undergraduate Research Initiative. Thank 
you particularly to Dr. Lee Kats and Katy Carr for administering the program.  
This project stemmed from Dr. Seshan’s Business Policy, Strategy and Ethics Capstone 
class. The topic of the project was an in depth analysis of the Swiss pharmaceutical company 
Roche. This project comes from the second part of the volume and has been modified to better 
suit this forum. I would also like to thank Dr. Seshan for his support and guidance on this 
endeavor. 
 You will notice that I have a co-author on this section, Alexander Anderson, who is a 
fellow Pepperdine Senior and also a member of the Capstone Class. We collaborated together on 
this particular segment. I would also like to thank and recognize Alex for his hard work and 
dedication. 
 Thank you again to everyone who made this program possible! 
 
Kindest Regards, 
 
Kali Jelen 
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Executive	  Memo	  
To: Academic Year Undergraduate Research Initiative Committee  
From: Kali Jelen 
Re: Alzheimer’s Disease Strategy for Roche Pharmaceuticals 
Date: December 11, 2014 
Critical Issues:  
Though once an industry leader in the Central Nervous System market segment, Roche 
Pharmaceuticals’ now holds only a fraction of a percent of market share in this segment. In 2013 
sales from drugs treating CNS diseases only amounted to $865 MM, about 1.6% of Roche’s total 
sales, falling 6% from 2012. Meanwhile the market as whole is growing rapidly. Between 2012 
and 2013 the CNS market segment grew 5.75% to $191 B. In order to retain overall Share of 
Market (SOM) Roche must find a way to keep up with the rapidly expanding CNS segment.  
 
Recommended Strategy:  
Roche should invest in the development of a new drug to treat Alzheimer’s Disease. A treatment 
for this progressive, fatal Central Nervous System Disease could help Roche to regain SOM in 
the Central Nervous System market segment. 
 
Justification:  
Alzheimer’s Disease is a progressive, fatal disease that affects 35 million people worldwide. In 
the next ten years the number of patients effected with Alzheimer’s is expected to increase 
drastically as the populations of developed countries age. Furthermore, the four treatments 
currently approved by the FDA are only effective for half the people who take them and can only 
the delay the onset of the disease by at most 12 months. Finally, Roche is better suited than any 
of its competitors to develop a new Alzheimer’s treatment thanks to the recent success of its 
subsidiary, Genentech’s, Crenzumab technology. 
 
Implementation Plan:  
Roche has the technology to develop a vaccine for Alzheimer’s. This strategy would take seven 
years to develop, test, and market. Roche will need to invest capital for Research and 
Development as well as new facilities. 
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Executive	  Summary	  
By:	  Kali	  Jelen	  
Findings- Alzheimer’s Disease is a degenerative illness that causes loss of memory and motor 
skills, changes in personality, and eventually results in death. The disease currently affects 35 
million people, worldwide, and yet no effective treatment option has yet been developed. The 
most prominent risk factors for the disease are age and the Apolipoprotein E4 gene. In the United 
States on in nine people over the age of 65 years and one in three over 85 years are suffering 
from Alzheimer’s/ Thanks to modern medicine and better living conditions, the life expectancy 
of people born in developed countries is increasing. In 2010 13% of the population of the United 
State (41 MM people) was over the age of 65. This number is forecasted to swell to 26% 
(approximately 90 MM people) by 2030. 
Results- The rapidly aging population of the United States and other developed nations and the 
prevalence of Alzheimer’s disease means that the market for an effective treatment option will 
increase greatly over the next ten years. Furthermore, Roche has lost its historical hold on the 
Central Nervous System Market Segment. Roche could greatly benefit from developing an 
effective treatment option for Alzheimer’s Disease. Roche’s subsidiary Genentech has been 
testing new technology that, thus far, has been more effective than any competitor at creating 
antibodies in the brain without causing dangerous swelling. 
Conclusions- Roche should use the technology developed at Genentech to create a new product 
that will treat Alzheimer’s, Aposecretase. Aposecretase will use existing technology to vaccinate 
against beta and gamma secretase enzymes, which are responsible for cutting the beta amaloid 
protein in to fragments thus forming plaque which inhibits brain function. This vaccine would 
strengthen the body’s natural antibody, microglia, to attack the enzument and protein fragments 
before they begin to accumulate. This vaccine has the potential to be profitable for Roche. The 
company is uniquely positioned to be a first mover on this new technology and the rapidly aging 
population will likely provide stable demand in the years to come. 
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Alzheimer’s	  Disease	  Strategy	  for	  Roche	  Pharmaceuticals	  
By:	  Alexander	  Anderson	  &	  Kali	  Jelen	  
Compiled	  By:	  Kali	  Jelen	  
Introduction	  
	  By:	  Kali	  Jelen	  
The Central Nervous System market segment is the second largest in the pharmaceutical 
industry, behind the Cardiovascular segment, according to Datamonitor, accounting for 19.6% of 
total industry sales.1 Drugs in this market segment seek to cure diseases relating to the brain and 
nervous system including Depression, Epilepsy, Psychosis, and Alzheimer’s disease.2 The 
Central Nervous System market segment is growing at a rapid rate. Between 2012 and 2013 total 
sales increased by 5.75% to 191 billion dollars.3  
Roche’s sales in the Central Nervous System segment amounted to approximately 865 million 
dollars for 2013, down approximately 6% from 2012.4 Central Nervous System segment sales 
only accounted for about 1.6% of Roche’s total 2013 sales of 52.5 billion dollars.5 Roche 
historically has been a leader in the Central Nervous segment due to their development of 
Valium and other sedatives. However over the past decade the company has slowly lost share to 
its competitors. Currently, Roche produces the drugs Dormicum, Madopar, and Valium to treat 
diseases of the Central Nervous System.6 Roche has an opportunity now to regain market share 
by developing drugs that specifically meet the complex needs of patients suffering from Central 
Nervous System diseases. 
Alzheimer’s disease is a progressive illness that causes problems with memory and thinking and 
changes in behavior and personality. It is a degenerative disease of the brain, which ultimately 
results in death. Alzheimer’s is the single most prevalent form of dementia and the sixth leading 
cause of death in the United States.7 Alzheimer’s primarily affects people aged 65 and older, 
though a small percent of people with the disease (less than 5%) are diagnosed with early onset 
Alzheimer’s, in which symptoms manifest themselves beginning when the patient is in their 40’s 
or 50’s.8 Alzheimer’s is a growing issue across the world, but particularly in the United States 
where one in nine people age 65 and older (11%) and one in three people over 85 (32%) are 
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suffering from the disease. In 2014 700,000 people are expected to die in the United States of 
Alzheimer’s related causes. 9 
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Exhibit 3.5.1 U.S. Annual Alzheimer’s Death Rates (per 100,000) by Age 
By: Kali Jelen 
 
Source: Latest Facts & Figures Report | Alzheimer's Association." Latest Facts & Figures Report | Alzheimer's Association. N.p., n.d. Web. 17 Oct. 2014. 
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Alzheimer’s is caused by a build-up of beta-amaloid protein fragments that are broken off of beta 
amaloid parent proteins (APP) by two enzymes, beta secretase and gamma secretase. These 
proteins stick together to form oligomers.10 Over time the oligomers multiply and collectively are 
known as plaque. All humans eventually develop a build-up of beta-amaloid protein fragments, 
however in Alzheimer’s patients the build-up is much faster and more prominent. The numerous 
oligomers find their way to the ends of the neurons (brain cells), which prevent synapses from 
firing and thus messages from being passed from one neuron to another.11 The oligomers also 
prevent proper nutrients from reaching neurons. The tau protein is responsible for providing the 
“tracks” in which nutrients pass over to reach the cell. The oligomers cause the tau proteins to 
collapse on themselves causing a tangle. These tangles prevent the neurons from getting proper 
nutrients.12 There are anti-bodies in the brain, which attempt to combat the oligomers called 
microglia. However due to the insoluble nature of the beta amaloid protein fragments they are 
not very effective.13 In the process of attempting to kill the amaloid protein fragments the 
microglia cause inflammation, which exacerbates the effects of the plaque. Eventually the lack of 
nutrients and firing synapses cause the deterioration of each affected neuron, resulting in 
memory loss, confusion, personality shifts, and mobility issues in those diagnosed with the 
disease. 14 
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Exhibit 3.5.2 Diagram of Plaque Affecting the Alzheimer’s Brain  
By: Kali Jelen 
 
Source: "Activation of Wnt Signaling Pathway Reverses Cognitive Deficits in an Alzheimer’s Disease 
Model." Developmental Biology Interactive. N.p., n.d. Web. 20 Oct. 2014. 
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The Alzheimer’s Association has identified three phases of the disease: Pre-clinical, Mild 
Cognitive Decline, and Dementia due to Alzheimer’s.15 During the first phase patients do not 
exhibit any symptoms, however significant brain changes begin to take place. It is impossible to 
diagnose at this stage. Doctors can only look at risk factors such as family history and the 
presence of the apolipoprotein E4 Gene to determine if the patient is likely to contract the 
disease.16 Phase one can last for more than twenty years. The next phase of Alzheimer’s is Mild 
Cognitive Decline. This is the point in which patients’ symptoms begin to manifest. During this 
stage patients will have difficulty remembering correct words and names, learning information, 
function in group work or social settings, remembering where things are, planning for the future, 
remembering personal history.17 These symptoms will worsen during the Dementia phase. 
Patients will begin to forget friends and family, have confusion about what day and year it is, 
experience a change in personality, lose awareness of surroundings, and have difficulty 
controlling bladder and bowels. Often during this time patients must be placed in a full time care 
situation. They will need assistance with daily tasks such as bathing, eating, and going to the 
bathroom. This final stage will continue to progress until patients lose the ability to speak and to 
respond to their surroundings.18 Their muscles become rigid, reflexes impair, and it becomes 
hard to swallow. The end of the progression is death, though often the effects of the symptoms, 
such as malnutrition because of the difficulty swallowing, is the actual cause of death. On 
average patients have only eight years to live from the start of phase one when symptoms begin 
to manifest themselves.19   
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Exhibit 3.5.3 Estimated Lifetime Risks for Alzheimer’s by Age and Sex 
By: Kali Jelen 
Source: Latest Facts & Figures Report | Alzheimer's Association." Latest Facts & Figures Report | Alzheimer's Association. N.p., n.d. Web. 17 Oct. 2014. 
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Currently there is no known cure for Alzheimer’s and only five drugs approved by the FDA to 
treat the symptoms of Alzheimer’s disease. These drugs are: Aricept (donepezil), Razadyne 
(galantamine), Namenda (memantine), Rivastigmine (Exelon), and Cognex (Tacrine) which are 
produced by Eisai Ltd., Janssen (Johnson & Johnson), Forest Laboratories (Actavis), Novartis, 
and Pfizer, respectively.20 Aricept, Rivastigmine, Razadyne, and Cognex are all cholinesterase 
inhibitors and work by preventing the breakdown of acetylcholine, an enzyme that allows 
messages to pass form neuron to neuron.21 The remaining drug Namenda works by preventing 
the breakdown of glutamate, a different neuron messenger and can be taken in conjunction with 
any of the cholinesterase inhibitors. All the five drugs have about the same success rate and can 
delay symptoms for 6-12 months for half of the people who take them.22 Cognex is the least 
popular of the medications as it comes with serious side effects such as kidney failure. It is not 
available in the United States at this time, but Pfizer still produces a limited amount of the 
drug.23  
Roche does not currently have an Alzheimer’s drug on the market and therefore is missing out on 
a valuable opportunity. It does however, through its subsidiary Genetech, have several 
Alzheimer’s drugs in the pipeline. None to this point have been successful though. By 
developing a new drug that fights the cause of Alzheimer’s rather than the symptoms Roche 
could easily corner the market and ensure that millions of people diagnosed each year with 
Alzheimer’s do not face a hopeless prognosis.  
Critical	  Issues	  
By:	  Kali	  Jelen	  
Currently there is a great need for a treatment that directly targets the cause of Alzheimer’s 
disease in the Central Nervous System market segment. Thirty five million people worldwide are 
suffering from Alzheimer’s and it effects one in nine people in the United States over the age of 
65 and one in three people over the age of 85.24 Currently those diagnosed with Alzheimer’s face 
a hopeless prognosis. 100% of those diagnosed with the disease will die with the disease, usually 
within eight years.25 In 2014, 700,000 Americans are expected to die of Alzheimer’s related 
causes.26 The situation will only get worse as the world’s population ages thanks to better 
medical technology and more hospitable social and environmental conditions. In the United 
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States for instance the population over the age of 65 is expected to reach 72 million by 2030. 
This will account for 20% of the United States total population, up from just 13% in 2010.27 Age 
is the single biggest risk factor for Alzheimer’s disease. In 2014 an estimated 5.2 million people 
were suffering from Alzheimer’s.28 
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Exhibit 3.5.4 Projected Number of People Age 65 and Older with Alzheimer’s in U.S. (2010-2050) 
By: Kali Jelen 
 
Source: Latest Facts & Figures Report | Alzheimer's Association." Latest Facts & Figures Report | Alzheimer's Association. N.p., n.d. Web. 17 Oct. 2014. 
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Because Alzheimer’s treatments currently only address the symptoms of the disease and not the 
causes of the disease, it is necessary to begin almost from scratch and try a new approach. Roche, 
with the help from its’ Genetech subsidiary, is in a unique position to develop a treatment option 
to prevent the onset and spread of Alzheimer’s, rather than just addressing the symptoms. Roche 
could use this opportunity to make up for previous losses in the Central Nervous System market 
segment by recapturing its competitive advantage. 
Roche and other pharmaceutical companies have been aggressively seeking to cure Alzheimer’s 
since effective testing technology became available in the early 1990’s.29 None, including Roche 
has yet been successful. Now however, is the perfect time for Roche to redouble is efforts as 
many pharmaceutical companies have pulled back research and development expenditures in the 
CNS market segment to focus resources on other areas.30 Competitors AstraZeneca, 
GlaxoSmithKline, Sanofi, and Merck have all but eliminated their CNS research and 
development pipeline, leaving plenty of room for innovation by Roche.31 
 Because of the nature of this venture the development of a completely new drug to fight 
Alzheimer’s will require a large outlay capital for research and development and startup costs. 
Research programs already in place will provide a solid base for the research to build off of.  
However, despite the initial costs and competition, if Roche is able to achieve this goal it will 
have a corner on the Central Nervous System market and be able to regain market share. 
Recommended	  Strategy	  
By:	  Kali	  Jelen	  
The recommended strategy for Roche, through Genetech, is to develop a new drug that prevents 
the causes of Alzheimer’s. Currently, an Alzheimer’s diagnosis is fatal within eight years. The 
five drugs approved by the FDA are not effective at preventing or reversing the disease, only in 
treating its symptoms. Many attempts have been made to attack the causes of Alzheimer’s, 
however none have been totally effective. In late 2014 Genentech began clinical trials for a new 
Alzheimer’s drug called Crenezumab. Crenezumab created a synthetic antibody to attack the 
beta amaloid protein fragments. At the midpoint of the study in July 2014 the project was 
deemed unsuccessful as the drug was not effective for a statistically significant number of 
patients.32 Despite the fact Crenzumab did not make it to market, it was the most successful 
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clinical trial thus far for medicines that seek to strengthen the body’s antibodies against the 
plaque. Crenzumab did not cause the dangerous brain swelling seen with other Alzheimer’s 
medications and therefore could be given in higher doses.33 
With the development of Aposecretase patients who are at risk of getting Alzheimer’s will be 
able to get a series of vaccines, administered through a nasal inhalant, which will target the two 
enzymes, beta secretase and gamma secretase, that cause the beta-amaloid protein fragments to 
break away from the beta-amaloid parent. This process will fortify antibodies in the brain know 
as microglia to attack the beta secretase and gamma secretase enzymes when they begin to create 
the beta-amaloid protein fragment which are responsible for forming the plaque which eventually 
kills patients neurons. Though the Aposecretase vaccine will not reverse the effects of 
Alzheimer’s disease, it can prevent the onset of the disease. The vaccine will be administered to 
all those with either one or two Apolipoprotein E4 Genes and those with a family history of 
Alzheimer’s.  
Aposecretase will be the first Alzheimer’s drug to attack the enzymes responsible for the creation 
of the beta-amaloid protein fragments rather than the fragments themselves. Though this process 
will not be able to reverse the effects of Alzheimer’s it will prevent more people from 
contracting the disease. Roche is well equipped for this task and become the first pharmaceutical 
company to successfully treat the cause of Alzheimer’s. 
Justification	  
By:	  Kali	  Jelen	  
Alzheimer’s affects 35 million people across the globe and there are currently no effective 
treatment options.34 The single biggest risk factor for Alzheimer’s is age.35 Thanks to modern 
medicine and better living conditions across the globe people are living longer. An aging world 
means more people will be diagnosed with Alzheimer’s. For example, in the United States by 
2030 20% of the population is expected to be over the age of 65. One in nine of those people will 
likely be diagnosed with Alzheimer’s.36 The need, and thus potential payoff, for an effective 
Alzheimer’s treatment is greater now more than ever. 
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Roche has the technical capability to create Aposecretase. With many competitors reducing the 
funds for CNS research and development, now is a better time than any to actively pursue a more 
effective Alzheimer’s treatment.  
Implementation	  Plan	  
By:	  Kali	  Jelen	  
The development of this new Alzheimer’s treatment will take approximately seven  years to get 
to market. Those seven  years will be spent researching and performing clinical trials to gain 
approval from governmental regulators. The initial outlay of capital for research and 
development will be $1.61 B. Though Roche already has a dedicated team of researchers for the 
CNS market segment, more researchers and specialists will need to be brought on to help speed 
the process. Furthermore, new, state of the art, facilities will be needed to house the operation. 
After the initial research and development phase Aposecretase will undergo inspection by the 
FDA and other government regulators to determine that it is safe. Once the Aposecretase is 
deemed safe clinical trials can be conducted. First, Roche will determine the effectiveness of the 
drug through a double blind trial using patients in the very early stages of the disease. Assuming 
that the effectiveness of the drug is proven Roche will move on to larger clinical trials involving 
3,000 patients or more. If Aposecretase continues to prove effective and not to have too many 
harmful side effects the dug will then finally be released to the market. Aposecretase will first be 
made available in the United States, followed by Europe, and then Japan. 
Next, Roche must ramp up production to meets the needs of millions of people who are at risk of 
contracting Alzheimer’s. Roche will use already existing production facilities in Hillsboro, 
Oregon repurposed to produce Aposecretase. Property, plant, and equipment dollars will be 
allocated to repurposing existing space and developing distribution channels. Because the 
manufacturing center is brand-new and state of the art, only minor changes will need to be 
implemented to achieve full functionality. 
At this point some marketing will be necessary to promote Aposecretase to doctors and hospitals 
and to train in its use. Doctors need to be taught to use existing genetic testing to screen for those 
likely to develop Alzheimer’s. Assuming the drug does not have any major side effects it will 
take on quickly as there are no other options for the treatment and prevention of Alzheimer’s. 
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Product	  Development	  
By:	  Kali	  Jelen	  
The product development of Aposecretase will begin with an initial research and development 
expenditure of 1.61 billion dollars. These costs will cover the salaries of additional researchers, 
new equipment, and acquisition of a new facility. Since this is an entirely new venture initial 
costs are quite high.  
After the initial research period Aposecretase will move in to the pipeline phase. An additional 
funds will be spend at this time to continue the research moving forward through several phases 
of clinical trials. This time will be used to flush out any unexpected side effects of the medication 
and to ensure that it is effective for most users.  
Roche will then need to manufacture the drug on a larger scale, which is when it will move to 
Genetech’s new state of the art facility in Hillsborough, Oregon. The plant, recently opened, still 
has available capacity to produce the new product.37  
Finally Roche will launch a limited marketing campaign for Aposecretase. The goal of this 
campaign will primarily be education of doctors and hospitals on the drug and its proper 
administration. Attention will also be paid to the importance of early diagnosis and the use of 
already established genetic testing to determine which patients are more at risk. 
Research	  and	  Development	  Expenditures	  
By:	  Kali	  Jelen	  
The initial investment in to research and development for this project is crucial to the success of 
Aposecretase. The initial capital outlay will cover expenses such as the hiring of new staff and 
the establishment of a new laboratory and headquarters just outside of Hillsboro, Oregon. Roche 
will seek out the foremost neurologists and geriatric experts to join their team. Furthermore, 
Roche will harness its subsidiary Genentech’s previous research to gain competitive advantage. 
Genentech’s Crenezumab is the closest any pharmaceutical company has come to producting a 
vaccine for Alzheimer’s. It is the only technology able to reach the microglia in the brain without 
causing dangerous swelling. Though the project has been set aside Roche will be able to use 
some of the advances rom Crenezumab to create Aposecretase. 
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Capacity	  Requirements	  
By:	  Kali	  Jelen	  
Roche will need labs and manufacturing facilities. In order to keep up with demand Roche will 
manufacture Aposecretase as the brand new state of the art plant in Hillsboro, Oregon that is set 
to open in 2015. The initial capital expenditure for this project will be $1.61 B. Some of which 
will be used to make minor alterations to the factory in Hillsboro and the rest will go towards 
labs and research facilities which will be off site.  
Strategic	  Fit	  
By:	  Kali	  Jelen	  
Roche’s development of Aposecretase will fulfill an unmet need in the pharmaceutical industry. 
Despite the fact that Alzheimer’s is the sixth biggest cause of death in the United States there are 
no effective, or even moderately effective treatment options.38 The problem of Alzheimer’s 
disease will only continue to grow as the population ages. Now is the perfect time to begin 
development of a new drug to stop the onset of this disease as the market will likely grow over 
the course of the next 20 years. 
Growth	  Opportunities	  
By:	  Kali	  Jelen	  
Roche does not currently have any products on the market for the treatment of Alzheimer’s. 
Currently there are 35 MM people in the world infected with Alzheimer’s disease and no 
effective treatment.39 The rapidly aging global population ensures that the number diagnosed will 
only continue to grow. Aposecretase will have extensive growth opportunities, especially in the 
Untied States and Japan where the population is aging more rapidly than the rest of the world.40 
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Financial	  Analysis	  
By:	  Kali	  Jelen	  
Income	  Statement	  Analysis	  
By:	  Kali	  Jelen	  
An income statement is used to summarize a firm’s revenue from product sales and firm’s 
expenses over a set financial accounting period in order to determine net income. A pro-forma 
income statement has been created for Aposecretase for the years of 2010-2032, which covers 
the period from the project’s inception to the expiration of the patent. The income statement 
covers Net Sales, Growth Rate of Sales, Cost of Goods Sold, Gross Margin, Selling Expenses, 
General & Administrative Expenses, Research & Development, Depreciation, Operating 
Expenses, Total Cost of Sales, Operating Income, Taxes, and Net Income.  
Net	  Sales	  
By:	  Kali	  Jelen	  
Net sales (revenue) is equal to the price of the drug multiplied by units sold expressed as a dollar 
amount. The pricing for this drug is much higher than current Alzheimer’s drugs because it will 
be administered as a three series inhalant vaccine, rather than a set of daily pills. Aposecretase 
will cost $10 K for one individual. Meaning that each administration will be cost approximately 
$3.3 K. Also, Aposecretase will do something that no other drug can, prevent Alzheimer’s from 
progressing by killing the enzymes that make the plaque. Currently treatments are ineffective and 
are only effective for about half the patients who take them.41 Even then though the best possible 
outcome is to delay the disease by several  months. The greater effectiveness of Aposecretase 
will justify its high price. The units sold will increase gradually each year, before leveling off 
when other competitor’s technology catches up.  
Cost	  of	  Goods	  Sold	  
By:	  Kali	  Jelen	  
Cost of Goods Sold describes the labor and raw materials expenditures that are made to produce 
a finished product. CoGS includes fixes costs and variable costs. Because no goods will be sold 
 21 
for the first six years there are no CoGS during. Only after 2020 when Aposecretase hits the 
market is does CoGS become relevant. According to the proforma income statement Cost of 
Goods sold will fluctuate between 20-25% of  Net Sales. Because aposecretase will develop out 
of the biotechnology sector the Cost of Goods sold will remain low. The Cost of Goods Sold is 
highest in the early years because it includes important costs such as those to establish a supply 
chain and distribution channels. After these initial expenditures efficiency will allow Cost of 
Goods Sold to decrease slightly. 
Gross	  Margin	  
By:	  Kali	  Jelen	  
Gross Margin is the difference between Net Sales and CoGS. The Gross Margin of Aposecretase 
will start at $2,975 MM in 2021 when the drug is first released and increase to $4,107 MM 
during 2032,  its final year before the expiration of the patent. Gross Margin will start out as 75% 
of Net Sales in 2021 and increase to 85% by 2032. This is due, in part, to the low Cost of Goods 
Sold in this industry. 
Selling,	  General,	  and	  Administrative	  Expenses	  
By:	  Kali	  Jelen	  
Selling, General, and Administrative expenses cover costs such as administrator hours and 
marketing fees. For Aposecretase the Selling, General, and Administrative expenses will be zero 
until 2021 when the drug is released. From 2021-2028  the cost will be relatively high as Roche 
must pay for a modest advertising campaign and educational materials for hospitals and doctors 
who will use the drug. In 2022 Selling, General, and Administrative expensis will be 20% of Net 
Sales before droppin down to 10% in 2023. In 2029 though this expense will drop off off as the 
market becomes aware of the product and remain so until the end of the patent in 2035. From 
2029 onward Selling, General, and Administrative expenses will only account for 5% of Net 
Sales.  
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Research	  and	  Development	  Expenditures	  
By:	  Kali	  Jelen	  
Research and Development is the single most important expenditure for all drug companies. 
R&D expenditures will cover researcher’s salaries, laboratories, research materials, and the cost 
of several studies to gain governmental approval. In 2014 when the project begins total R&D 
expenditure will be $120 MM. The R&D expenditure will increase at a steady rate of 5% for the 
useful life of the product. In 2021 when Aposecretase is released R&D Expenditure will be 
$436.2 MM and account for 12% of Net Sales. By the final year of Aposecretase’s patent, 2032, 
R&D Expenditure will equal $746.05 MM and account for 14% of Net Sales.  
It is incredibly important for Roche to keep up its R&D expenditures to avoild falling over a 
patent cliff. If Roche is unable to innovate a new treatment option or a variation of acurrent 
treatment option by 2032 the company will experience a major decrease in revenue. 
Depreciation	  
By:	  Kali	  Jelen	  
Depreciation is an accounting tool used to represent the physical wear and tear over time on 
equipment and other tangible assets. Depreciation is listed on the pro-forma income statement as 
a non-cash charge. Depreciation is calculated using the useful life of property, plant, and 
equipment and assets’ salvage value.  
For Aposecretase, straight line depreciation was used to determine the depreciation schedule. 
Each year the depreciation expense increases until the patent expires.  
Depreciation is $76.76 MM dollars in 2014 and ends at $175.31 MM in 2032. Depreciation 
accounts for approximately 3% of Net Sales throughout the life of the patent. 
Earnings	  before	  Interest	  &	  Taxes	  (EBIT)/Operating	  Income	  
By:	  Kali	  Jelen	  
Earnings before interest and taxes (EBIT), also known as operating income, is calculated by 
subtracting Cost of Sales from net sales. Operating income is an important factor in determining 
the commercial success of a product. While Aposecretase is in the pipeline stages EBIT is zero. 
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However, when it hits the market in 2021 EBIT increases to $1,894 MM, which is 75% of net 
sales. By 2026 EBIT levels off to 53% of Net Sales or $2,224 MM and at the end of 
Aposecretase’s patent life EBIT will account for 57% of Net Sales or $2,929 MM. 
Taxes	  
By:	  Kali	  Jelen	  
For this project Roche is taxed at a rate of 12-29%. While Aposecretase is still in the pipeline 
Roche is not required to pay taxes as it is operating at a loss. By 2021 though, Roche will have to 
pay $1,894 MM in taxes. By the end of the drug’s patent life in 2032 Roche will have to pay 
$1,464 MM in taxes. The pharmaceutical industry as whole does not face an exceptionally high 
tax rate and therefore it is reasonable to assume that Roche will be taxed at a relatively low rate 
for the duration of this project. 
Net	  Income	  
By:	  Kali	  Jelen	  
Net income is an important factor in determining the success of a given venture. It is calculated 
by subtracting all the production expenses, including cost of goods sold, operating expenses, and 
taxes from the net sales. Net income is negative while Aposecretase is in the pipeline and during 
the first years of sales, but becomes positive in 2021 during Aposecretase’s first year of sales. In 
2021 the Net Sales for this project will be $1,894 MM. Net Income will befor 27-29% of Net 
Sales during the life of the product. Net Sales will first be 29% in 2030 when the product has 
reached its full maturity.  
Balance	  Sheet	  Analysis	  
By:	  Kali	  Jelen	  
The Balance sheet is a snapshot of a company’s financial position at a given period of time. It 
details a company’s assets, liabilities, and stock holder equity. The pro-forma Balance sheet 
below covers 21 years beginning in 2014 and ending in 2032. 
 24 
Assets	  
By:	  Kali	  Jelen	  
Total assets are made up of current assets and fixed assets. Current assets are defined as those 
assets that will be realized within one year, while fixed assets are those non-liquids holding that 
cannot or will not be converted to cash in one year. Maintaining current assets is important as it 
indicates a company is in a position to pay off its debts. In 2014 Total Assets for this strategy 
will be $1627 MM. Total Assets will increase at a fairly constant rate from 2014-2021 when 
Aposecretase is released. In 2021 the Total Current Assets will shoot up to $5,351 MM. Total 
Assets will remain high throughout the lifetime of the strategy. Ending up in the final year of the 
patent (2032) at $6,583 MM. 
Liabilities	  
By:	  Kali	  Jelen	  
Like assets, Liabilities are classified in to two categories: current and long term. Current 
liabilities must be paid within one year while long term liabilities take longer to pay off. 
Liabilities include any debts the company may owe, whether short term to suppliers or long term 
to banks. Roche will accumulate $3,496 MM in Total Liabilities by 2021. Though Total 
Liabilities will decrease over the life of  the strategy, but fluctuate slightly. In 2026 Total 
Liabilities will be $3,458 MM or  53% of Total Assets. By the final year of the patent in 2032 
will be $3,543 MM or 54% of Total Liabilities. 
Stockholders’	  Equity	  
By:	  Kali	  Jelen	  
Stockholders’ equity is another name for retained earnings. It is calculated by subtracting total 
liabilities from total assets. Assets equal liabilities plus retained earnings. In 2014 Stockholder’s 
equity amounts to  $1,627 MM but increases as Aposecretase becomes more profitable. In 2021 
Stockholder’s Equity will be $1,855 MM or 35% of Total Assets. By 2026 this number will 
become $3,083 MM or 47% of Total Assets. By the final year of the Aposecretase patent 
Stockholder’s Equity will be $3,041 or 46% of Total Assets. 
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Statement	  of	  Cash	  Flow	  Analysis	  
By:	  Kali	  Jelen	  
A statement of cash flows analyzes the changes in operations, investments, and financing that 
alters the cash reserves of a company during a set period of time. The pro-forma statement of 
cash flows below covers a 21 year period from 2014 to 2034. 
Permanent	  Investment	  
By:	  Kali	  Jelen	  
Permanent investment is the combination of property, plant, and equipment expense and research 
and development expenditure. It describes the long term capital investments in to the project. In 
2014 the permanent Investment is $1,920 MM. This increase steadily over the life of the 
strategy. By 2026 the total permanent investment  has $3,551 MM. By the end of the Pro-Forma 
Permant Investment Worksheet in 2035 Total Permanent Investment will have reached $4,808 
MM. Total Permanent Investment is used to calculate Working Capital. 
Net	  working	  Capital	  
By:	  Kali	  Jelen	  
Net working capital is the difference between Current Assets and Current Liabilities. It is 
imperative to maintain net working capital in order to continue productions. Negative Change in 
Networking Capital indicates the liquidation of assets, thus limiting the production capabilities of 
an organization. For Aposecretase Working Capital will begin in 2014 at $95 MM and grow 
from there. By 2021 when Aposecretase is first released Net Working Capital will be $147 MM. 
By 2026 this number will have increased significantly to $1,553 MM and by 2035 the  Working 
Capital will have reached $1,935 MM. The Change in Net Working Capital is consistently 
positive for Aposecretase. 
Cash	  Outflow	  
By:	  Kali	  Jelen	  
Cash outflow is calculated by combining the change in permanent investment with net working 
capital. The cash outflow for Aposecretase is greates in 2014 at $1,920 MM, but declines 
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significantly throughout the life of the patent. In 2021, the first year of sales, cash outflow ill be 
$151 MM. By 2026 Cash Outflow will be $289 MM and in 2035 it will be $157 MM. Cash Out 
flow is important to determining the Cumulative Cash Flow and thus the Cumulative Discounted 
Cash Flow which indicates the viability of a given project. 
Cash	  Inflow	  
By:	  Kali	  Jelen	  
Cash inflow is calculated by adding depreciation to net income. Cash inflow is negative during 
the pipeline phase but turns around quickly as soon as the product hits the market in 2021. In 
2014 Cash inflow is -$310 MM. Cash Inflow remains negative until 2021 when it becomes 
$2,013 MM.  Cash inflow remains positive through the compeletion of the project in 2035. 
Net	  Cash	  Flow	  
By:	  Kali	  Jelen	  
Net cash flow is simply the difference between cash inflow and cash outflow. It is an important 
part of the financial analysis because it takes in to account all prior losses and can pinpoint 
exactly when a project can be expected to become profitable.  For Aposecretase the net cash flow 
will become positive in 2021 during the first year of sales. 
Cumulative	  Net	  Cash	  Flow	  
By:	  Kali	  Jelen	  
Cumulative net cash flow is a summation of the net cash flow for all the previous years. It is a 
helpful measure as it describes the year in which a project reaches cash recovery. Aposecretase 
will meet this marker in . 
Cumulative	  Discounted	  Net	  Cash	  Flow	  
By:	  Kali	  Jelen	  
The cumulative discounted net cash flow is the summation of net cash flow discounted to the 
year of the project’s initiation, which for aposecretase is 2014. Net Cash flow is discounted at a 
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rate of 10% to account for inflation and the weighted average cost of capital. For Aposecretase 
the strategy cumulative discounted net cash flow is negative until year end 2023. 
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Exhibit 3.5.5 21 Yr. Net Sales Forecast $MM- Company: Roche- Aposecretase (2014-2032) 
By: Kali Jelen 
 
Source: Seshan, V. Ph.D. Strategic Management Financial Analysis and Cash Flow. Fourteenth Edition. Cengage. Manson, OH. CD-ROM. 2013. 
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Exhibit 3.5.6 21 Yr. 30 Yr. Depreciation Schedule $MM- Company: Roche - Aposecretase (2014-2025) 
By: Kali Jelen 
 
Source: Seshan, V. Ph.D. Strategic Management Financial Analysis and Cash Flow. Fourteenth Edition. Cengage. Manson, OH. CD-ROM. 2013. 
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Exhibit 3.5.7 21 Yr. 30 Yr. Depreciation Schedule $MM- Company: Roche - Aposecretase (2026-2035) 
By: Kali Jelen 
 
Source: Seshan, V. Ph.D. Strategic Management Financial Analysis and Cash Flow. Fourteenth Edition. Cengage. Manson, OH. CD-ROM. 2013  
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Exhibit 3.5.8 21 Yr. 21 Yr. Pro-Forma Income Statements $MM- Company: Roche - Aposecretase (2014-2019) 
By: Kali Jelen 
 
Source: Seshan, V. Ph.D. Strategic Management Financial Analysis and Cash Flow. Fourteenth Edition. Cengage. Manson, OH. CD-ROM. 2013. 
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Exhibit 3.5.9 21 Yr. 21 Yr. Pro-Forma Income Statement $MM- Company: Roche - Aposecretase (2020-2025) 
By: Kali Jelen 
 
Source: Seshan, V. Ph.D. Strategic Management Financial Analysis and Cash Flow. Fourteenth Edition. Cengage. Manson, OH. CD-ROM. 2013. 
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Exhibit 3.5.10 21 Yr. 21 Yr. Pro-Forma Income Statement $MM- Company: Roche - Aposecretase (2026-2032) 
By: Kali Jelen 
 
Source: Seshan, V. Ph.D. Strategic Management Financial Analysis and Cash Flow. Fourteenth Edition. Cengage. Manson, OH. CD-ROM. 2013. 
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Exhibit 3.5.11 21 Yr. 21 Yr. Pro-Forma Balance Sheet $MM- Company: Roche - Aposecretase (2014-2019) 
By: Kali Jelen 
 
Source: Seshan, V. Ph.D. Strategic Management Financial Analysis and Cash Flow. Fourteenth Edition. Cengage. Manson, OH. CD-ROM. 2013. 
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Exhibit 3.5.12 21 Yr. 21 Yr. Pro-Forma Balance Sheet $MM- Company: Roche - Aposecretase (2020-2025) 
By: Kali Jelen 
 
Source: Seshan, V. Ph.D. Strategic Management Financial Analysis and Cash Flow. Fourteenth Edition. Cengage. Manson, OH. CD-ROM. 2013. 
  
 36 
Exhibit 3.5.13 21 Yr. 21 Yr. Pro-Forma Balance Sheet $MM- Company: Roche - Aposecretase (2026-2032) 
By: Kali Jelen 
 
Source: Seshan, V. Ph.D. Strategic Management Financial Analysis and Cash Flow. Fourteenth Edition. Cengage. Manson, OH. CD-ROM. 2013. 
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Exhibit 3.5.14 21 Yr. 21 Yr. Schedule of R&D Expenditures $MM- Company: Roche - Aposecretase (2014-2032) 
By: Kali Jelen 
 
Source: Seshan, V. Ph.D. Strategic Management Financial Analysis and Cash Flow. Fourteenth Edition. Cengage. Manson, OH. CD-ROM. 2013.  
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Exhibit 3.5.15 21 Yr. 21 Permanent Investment Worksheet $MM- Company: Roche - Aposecretase (2014-2032) 
By: Kali Jelen 
 
Source: Seshan, V. Ph.D. Strategic Management Financial Analysis and Cash Flow. Fourteenth Edition. Cengage. Manson, OH. CD-ROM. 2013. 
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Exhibit 3.5.16 21 Yr. 21 Cash Flow Projections $MM- Company: Roche - Aposecretase (2014-2032) 
By: Kali Jelen 
 
Source: Seshan, V. Ph.D. Strategic Management Financial Analysis and Cash Flow. Fourteenth Edition. Cengage. Manson, OH. CD-ROM. 2013. 
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Exhibit 3.5.17 21 Yr. 21 Yr. Cumulative Cash Flow Projection Graph $MM- Company: Roche - Aposecretase (2014-2032) 
By: Kali Jelen 
 
Source: Seshan, V. Ph.D. Strategic Management Financial Analysis and Cash Flow. Fourteenth Edition. Cengage. Manson, OH. CD-ROM. 2013. 
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Environmental	  Threats	  and	  Opportunities	  Profile	  Using	  TIPSEEECS	  
By:	  Alexander	  Anderson	  
Introduction	  
By:	  Alexander	  Anderson	  	  
An environmental scan is one of the best tools to analyze and identify the impact of both internal 
and external Threats and Opportunities.  The Environmental Threats and Opportunities Profile 
(ETOP) uses a model that is made up of nine different factors.  These include Technology, 
International, Political, Social, Ecological, Energy, Economic, Competition, and 
Spirit/Ethics/Spirituality (TIPSEEECS).42  In the TIPSEEECS model the impact of each of the 
factors is then ranked.  If a factor is considered to be a Threat it is valued with a negative number 
ranging from -5 (very strong) to -1 (very weak).  If the factor is considered an Opportunity it is 
given a positive number ranging from 1 (very weak) to 5 (very strong).  In addition, the 
importance associated with each factor is ranked from 1 (unimportant) to 10 (very important).43  
The impact and importance of each factor are then multiplied together to produce an ETOP 
Value to help assess how much factor effects the organization.   
Technology	  	  
By:	  Alexander	  Anderson	  	  
When looking at the role of Technology in relation to Alzheimer’s disease it is important to note 
the crucial role of the biotechnology industry along with the pharmaceutical industry.  
Biotechnology is the application of science and technology to living organisms.44  The 
importance of the biotechnology industry has led to pharmaceutical companies acquiring 
biotechnology companies, due to the benefits of developing treatments for disease with a 
combined effort.  Roche recently agreed in August to pay $8.3B to acquire InterMune, a 
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California biotech firm that has yet to turn a profit on a new drug to treat a deadly lung disease.45  
Protein-related technologies are deployed specifically for research and development of 
therapeutic proteins.  These therapeutic proteins are the most important group of 
biotechnological currently in use.  Roche owns and develops cutting edge protein-engineering 
technologies as well as world-class manufacturing processes and facilities.46  One such protein is 
Brain Shuttle, a technology that Roche developed to increase penetration of large molecules such 
as antibodies into the brain.47   
Within the biotechnology industry there is a high level of proprietary knowledge.  Due to the 
high levels of technology required within the industry for specialist technologies, buildings, and 
equipment associated with the cost of research, new biotechnology companies tend to require a 
large amount of capital, as they are known for long start up periods with little profit and high 
fixed costs.48  This creates barriers to entry for new companies.  As a result, Technology is 
considered to be a large opportunity within the industry as developing technologies and new 
research leads to advances in the understanding of disease and prevention.   
International	  	  
By:	  Alexander	  Anderson	  	  
Alzheimer’s disease is a global challenge.  It is the most common form of dementia and can 
destroy memory and thinking skills as the condition progresses. Currently there are 44 million 
people with dementia worldwide; thirty-five million of them are suffering from Alzheimer’s.  
Diagnoses are on the rise with 76 million people expected to be living with dementia by 2030.  
Global collaboration is needed to transform Alzheimer’s disease research and treatment.49   
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Politics	  	  
By:	  Alexander	  Anderson	  	  
The Biotechnology Industry is effected by politics via the regulations set by governing bodies.  
Regulations have become stricter, especially in the medical field, requiring lengthy and costly 
clinical trials to prove product effectiveness and safeness.  The regulations are initiated by the 
Food and Drug Administration (FDA).  The FDA’s goal is to protect and promote the health of 
the nation by regulating the drugs on the market.  This acts as a threat to the industry as 
regulations have become stricter and the time required for FDA approvals have increased as 
well.  In 2009, the FDA implemented a series of reforms that included stricter monitoring of drug 
adverse events, more funding for the agency, stronger ability to force product recalls, and more 
scientific expertise within the agency. Thus, the FDA has become more reluctant to approve a 
high amount of drugs to be released on the market.  
President Obama has signed an executive order that lifts the restrictions on stem cell research 
funding.  Stem cell research can play a key role in the development of new treatments, as it 
allows for studies in genetic patterns.50  However, there are many ethical implications as related 
to stem cell research, which can make Biotechnology companies hesitant over experimenting to 
discover new developments.   
Social	  	  
By:	  Alexander	  Anderson	  	  
The population of baby boomers, those considered to be a part of the shockwave of babies born 
after World War II, are growing older and becoming part of the elderly population. As a result 
they tend to be in high demand for new treatments for disease.  Alzheimer’s disease is the most 
common form of dementia and can destroy the memory and thinking skills as the condition 
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progresses.  Currently there are forty-four million people with dementia worldwide; thirty-five 
million of them are suffering from Alzheimer’s.  Diagnoses are on the rise with seventy-six 
million people expected to be living with dementia by 2030.  Collaboration is needed to 
transform Alzheimer’s disease research and treatment to find a way to prevent this devastating 
disease.   
Ecology	  	  
By:	  Alexander	  Anderson	  	  
The ecological factor is another important consideration when it comes to expanding into a new 
market.  Although there is not any evidence that there is a link between the environment and 
Alzheimer’s disease, efforts can still be made for developing sustainable ecological trends.  As 
society faces the harmful influences it has the environment it has the opportunity to make 
ecological improvements on the processes to reduce a company’s ecological footprint.  The need 
to support clean energy, reduce pollution from carbon emissions, conservation, and recycling is 
crucial for the environment but also helps keep a company sustainable in the long run.51   
Energy	  	  
By:	  Alexander	  Anderson	  	  
Similar to ecology, currently there is no evidence that the energy factor does not play a direct 
role in Alzheimer’s disease.  Despite this, energy is also an important factor to consider when 
expanding into a new market.  Parallel to the mentality that a company wants to consider the 
environment in relation to its processes, a company also needs to consider how much energy it is 
using and where that energy is coming from.  If fossil fuels are being used to provide energy the 
environment will suffer.  On the other hand if hydro power, wind, or solar power are sued there 
is a limitless amount of energy available with a minimal environmental impact.52   
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Economics	  	  
By:	  Alexander	  Anderson	  	  
Roche’s sales in the Central Nervous System segment amounted to approximately $865MM for 
2013, about a 6% reduction from 2012.  It accounts for only 1.6% of Roche’s total 2013 sales of 
$52.5B.  At the same time, the Central Nervous System market segment is growing at a rapid 
rate, between 2012 and 2013 total sales increased by 5.75% to $191B.  As the Central Nervous 
System market segment is the second largest in the Pharmaceutical Industry Roche has an 
opportunity to regain market share by developing a drug for Alzheimer’s disease.  Alzheimer’s 
already affects 35 million people across the globe and there are currently no effective treatment 
options.  As people live longer thanks to modern medicine more people will be diagnosed with 
Alzheimer’s.   
Competition	  	  
By:	  Alexander	  Anderson	  	  
Many competitors are reducing the funds for CNS research and development.  This creates a 
great opportunity to pursue a more effective Alzheimer’s treatment with little to no competition 
currently in that market.  With Aposecretase being the first drug of its type on the market, it 
possesses the ability to gradually generate high monetary sales; however, other companies will 
most likely begin to develop similar treatments soon thereafter.   
Patent expirations of drugs also pose as a threat, as it is an opportunity for competitors to take 
over market share.  This is why, new developments in Research and Development are a 
necessary part of the industry.  Aposecretase would currently have no competitors in the market 
because there is no other treatment of its kind on the market.  Once released developments will 
need to continue to ensure a competitive edge on other companies that would like to take over.  
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Competition definitely presents a threat to Roche but it can be managed with proper scanning of 
the industry.   
Spirit/Ethics/Spirituality	  	  
By:	  Alexander	  Anderson	  	  
The Biotechnology Industry can be controversial as people struggle with concerns related to 
Spirit, Ethics, and Spirituality.  Though President Obama overturned President Bush's policy for 
limitation on stem cell research funding, other policies need to be developed to protect human 
interest and other ethical concerns.  Eventually Alzheimer’s leads to death not from being sick 
directly but usually from malnourishment as those with it eventually struggle to even swallow 
food.  Add the fact that these people are not even themselves anymore because they have 
forgotten everything that makes them who they are.  As such the argument can be made that to 
not peruse a treatment is just as bad as any tests that may need to be performed.  Every action 
and decision has both Pro's and Con's associated with the outcome.  However, if the Pro's 
outweigh the Con's it will greatly benefit society, but if it puts certain ethical values into question 
then the strategy must be reevaluated.   
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Exhibit 3.5 18: Roche ETOP Graph 2014 
By: Alexander Anderson  
Worksheet 1.2 
         Strategy #3:  Aposecretase                                       V.Seshan 
  
          EXHIBIT 16.12 - Environmental Threats & Opportunities Profile (ETOP)  
  Alzheimer's Disease CNS Market Segment 
            
Factors 
Impact of 
Factor   
Importance of 
Factor   
Environmental 
Threat/Opportunity   Rank 
  Competition -3 
 
8 
 
-24 
 
1 
  Politics -2 
 
5 
 
-10 
 
2 
  Spirit / Ethics -4 
 
4 
 
8 
 
3 
  Ecology 1 
 
3 
 
3 
 
4 
  Energy 1 
 
2 
 
2 
 
5 
  International 2 
 
5 
 
10 
 
6 
  Social 3 
 
7 
 
21 
 
7 
  Economics 4 
 
8 
 
32 
 
8 
  Technology 5 
 
10 
 
50 
 
9 
  
   
Total ETOP Score 
=  
 
73 
              Impact is ranked from -5 (strongly negative) to +5 (strongly positive). 
    Importance if ranked from 1 (unimportant) to 10 (very important). 
     
          Comments: The Central Nervous System market segment is the second largest in the pharmaceutical 
industry and grew by 5.75% between 2012 and 2013.  At the same time it only accounts 
for 1.6% of Roche's total 2013 sales.  Roche has an opportunity to regain market share 
by developing a drug for Alzheimer's disease.  Alzheimer's already affects 35 million 
people and there are currently no effective treatment options.  As people live longer due 
to modern medicine more people will be diagnosed with Alzheimer's.  At the same time, 
Roche needs to continually improve to stay ahead of its competition as well as satisfy 
governing bodies who are concerned for the safety of the public.   
            Source: 
Rowe, Alan J. , Mson, Richard O., Dickel, Karl E., Mann, Richard B., Mockler. Robert J., Strategic Management- A 
Methodological Approach. 4th Ed. 1999, Reasing, MA: Addison- Wesley. Page 115. TIPSEECS Model Copyright 
By: Dr. V. Seshan 
Mann, Rowe, and Seshan, Strategy for the 21st Century, Pages 75-81, IBT Global, Edition 5.5, 2011  
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Stakeholder	  Analysis	  	  
By:	  Alexander	  Anderson	  	  
Introduction	  	  
By:	  Alexander	  Anderson	  	  
Stakeholders are individuals or groups that can affect the organization or those who are affected 
by the organization’s actions. They all have stakes in the organization and each stakeholder is 
counting on the organization to achieve its goals.  Because all stakeholders have a claim on the 
company, it is up to the managers and executives to further the success of the organization.53   
Performing a Stakeholder Analysis allows executives to determine who their stakeholders are 
and allows them to build mutual interactive relationships with stakeholders in order to achieve 
their goals and improve upon the organization. In order to do this, the managers of the company 
must evaluate the importance of their goals and minimize problems that may arise as a result.54  
A Stakeholder Analysis gives a visual representation on who the Internal Stakeholders and 
External Stakeholders are.55   
A Stakeholder Analysis is performed by identifying the stakeholders and evaluating their 
association to the company.  This allows managers to analyze the opportunities and threats 
presented with each stakeholder.  The analysis assigns assumptions to given stakeholders and 
looks at the supporting and resisting forces these stakeholders can have on the organization.  
Executives evaluate these factors and organize strategies that will best serve the organization.56   
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Exhibit 3.5 19: Roche Steerer Model 2014  
By: Alexander Anderson 
	  
Source:  
Rowe, Alan J., Mason, Richard O., Dickel, Karl E., Mann, Richard B., and Mockler, Robert J. 
"Stakeholder Analysis." Strategic Management - A Methodological Approach. Fourth 
Edition. Addison-Wesley. New York. Page 141. 1999.  
Seshan, V. Ph.D. "Stakeholder Analysis." Strategic Management Financial Analysis and Cash 
Flow. Thirteenth Edition. Thomson. Mason, OH. CD-ROM. 2012.	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Internal	  Stakeholders	  	  
By:	  Alexander	  Anderson	  	  
Management	  and	  Employees	  	  
By:	  Alexander	  Anderson	  	  
The person responsible for pursuing the long-term interests of the company and its stakeholders 
is the Chief Executive Officer.  As such the CEO is critical to the company's success.  Duties 
range from engaging in strategies that contribute to the organization's overall business growth as 
well as selecting management to monitor that growth.  The CEO of Roche since 2008 is Dr. 
Severin Schwan.57  Schwan brings a relentless drive for innovation and a passion for 
personalized healthcare.  He joined Roche in 1993 as a trainee and has stayed with the company 
ever since.  He is fascinated with Roche because "we can literally save millions of lives and 
improve the quality of life of millions of patients and their families".58  Schwan earned his 
Doctorate in Law at University of Innsbruck in Belgium.  He has been a member of the Board of 
Directors of Roche Holding Ltd, the European Round Table of Industrialists, the Board of 
Directors of Credit Suisse Group, and the International Business Leaders Advisory Council for 
the Mayor of Shanghai.  He says, “Proud as we are of our past and present achievements, what 
really excites us, however, is the future.”  The pursuit of a cure for Alzheimer’s disease lines 
right up with what Schwan has been doing and wants to do in the future.   
Roche believes that employees who are engaged are key to delivering the highest standards and 
the greatest levels of innovation.  Three values sustain the culture and further the quest to help 
people achieve good health and longevity: integrity, courage and passion.59  Roche aspires to 
embody these values in everything it does.  All of this points to the fact that both the employees 
and their managers will accomplish the strategy of finding a cure for Alzheimer’s disease.   
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Research	  and	  Development	  Department	  	  
By:	  Alexander	  Anderson	  	  
Roche has a strong corporate culture where employees are engaged, diversified, and balanced.  
Currently there are more than 18,000 employees working on research and development to deliver 
medical innovations.60  The scientists at Roche are passionate about helping people combat the 
world’s hardest-to-treat diseases.  To ensure a strong pipeline there is a network of Research and 
Development centers around the world.  In addition to the R&D centers, Roche makes clinical 
study reports available to qualified researchers for further scientific study.  This worldwide 
partnering expands innovation network in the area of in vitro diagnostics.61   
Roche has positioned itself to fit the treatment of the patients by working in bot Pharmaceuticals 
and Diagnostics.  It believes that finding innovative solutions for serious, currently unsolved 
medical problems is what a healthcare company is all about.  Roche employees strive to create 
clinically differentiated drugs and diagnostic tests to enable tangible improvements in the health, 
quality of life and survival of patients.  These R&D mentalities are exactly what is needed when 
trying to come up with a solution Alzheimer’s disease.62   
Stockholders	  	  
By:	  Alexander	  Anderson	  	  
Shareholders are important Stakeholders in any project a company develops.  The goal of every 
corporation should be to maximize shareholder wealth.  A shareholder can be defined as a 
"person, company, or other institution that owns at least one share in a company".  Also referred 
to as a Stockholder, a Shareholder has the potential to profit if the company has financial 
success, however also has the potential to experience losses if the company performs poorly.63  
The success of Aposecretase for Roche has the opportunity to provide profit for Shareholders 
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and keep them invested within the company.  Stockholders are important to Roche’s 
development of Aposecretase because it is one of the means of raising capital for further 
Research and Development.  Aposecretase gives Roche the chance to dominate an untapped 
market by helping fight Alzheimer’s disease.   
External	  Stakeholders	  	  
By:	  Alexander	  Anderson	  	  
Consumers/Patients	  	  
By:	  Alexander	  Anderson	  	  
Customers' needs and wants are vital to Roche’s financial success, which makes them Roche’s 
most important stakeholder.  Roche is urgently trying to deliver patients medical solutions right 
now while it develops innovations for what they need next in the future.  Customers are the 
biggest External Stakeholders as they generate sales and thus profit for the corporation.  As a 
new drug with benefits exclusive to itself, Aposecretase will come at a higher cost of production. 
This cost will be passed down as a higher selling price once it is released into the market.  The 
high cost will be determined through the level of research involved, the technologies required for 
development, resources used, and other additional costs.  Despite the high cost of treatment, 
patients will likely want to purchase Aposecretase and have the means to do so given their 
mature age and desire to prevent any of their conditions from worsening.   
Government	  Regulation	  	  
By:	  Alexander	  Anderson	  	  
The U.S. Food and Drug Administration (FDA) has a large stake in determining Roche’s success 
as it has the authorization to approve or reject Roche’s products. It is the FDA's duty to protect 
people by assuring the safety, efficacy, and security of drugs, biological products, and medical 
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devices.64  What makes the FDA even more vital to Roche’s success is that it has the power to 
promote public health by speeding up the process in which medical products are approved.  It is 
also the FDA’s responsibility to make sure the public has enough available knowledge in 
understanding the drugs in which they are taking to improve their health.65  Complying with 
FDA standards is crucial to the development process, as Roche does not want its products to 
have adverse effects on customers.   
Suppliers	  	  
By:	  Alexander	  Anderson	  	  
Roche makes their foals of integrity and transparency integral to their business.  Their supplier 
objectives are aligned with the Roche Group strategy as include key performance indicators and 
targets.  Remaining in alignment with their mission, Roche relies on a large and diverse supply 
network to bring innovative medicines and diagnostics to people who need them.66  Roche 
established procurement procedures and take steps to make sure that their partners adhere to the 
same principles.  At the same time Roche invites its suppliers to work with them on improving 
the sustainability of the supply chain.  All of this is in the name of innovation and performance 
and risk management.67   
Competitors	  	  
By:	  Alexander	  Anderson	  	  
Many competitors are reducing the funds for CNS research and development.  As mentioned 
above, this creates a great opportunity to pursue a more effective Alzheimer’s treatment with 
little to no competition currently in that market.  While Aposecretase has great potential to grow 
and generate high monetary sales due to its position in the market, once other companies see the 
success they will begin to develop similar treatments and follow suit.  This is why, new 
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developments in Research and Development are a necessity.  Aposecretase would currently have 
no competitors in the market because there is no other treatment of its kind on the market.  Once 
released developments will need to continue to ensure a competitive edge on other companies 
that begin to move into the same market segment.  Competition definitely presents a threat to 
Roche but it can be managed to effect Roche in a lesser way for a longer period of time.   
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Exhibit 3.5 20: Roche Internal Stakeholder Assumption Graph 2014 for Aposecretase, CNS 
Segment Strategy 
By:	  Alexander	  Anderson	  	  
Stakeholders	   Major	  Assumptions	   Importance	   Certainty	  
1.	  Management	  
and	  Employees	  
Supporting:	  	  
a. CEO	  has	  a	  relentless	  drive	  for	  innovation	  
b. Engaged	  employees	  will	  deliver	  the	  high	  
standards	  and	  levels	  of	  innovation	  	  
	  
7	  
4	  
	  
9	  
4	  
	   Resisting:	  	  
a. Large	  failure	  in	  development	  is	  a	  waste	  of	  
capitol	  allocation	  
b. Poor	  management	  allocated	  to	  research	  
	  
5	  
	  
3	  
	  
4	  
	  
2	  
2.	  Research	  and	  
Development	  
Department	  
Supporting:	  	  
a. Competitive	  R&D	  department	  has	  led	  to	  
Roche	  being	  one	  of	  the	  greatest	  	  
b. Partners	  are	  on	  the	  same	  page	  as	  Roche	  
	  
5	  
	  
7	  
	  
7	  
	  
5	  
	   Resisting:	  	  
a. Untapped	  market	  where	  little	  is	  known	  
about	  Alzheimer’s	  disease	  	  
b. High	  costs	  associated	  with	  new	  research	  
	  
8	  
	  
8	  
	  
7	  
	  
8	  
3.	  Stockholders	   Supporting:	  	  
a. Acquisition	  of	  other	  companies	  
b. Leading	  biotechnology	  and	  
pharmaceutical	  company	  
	  
7	  
7	  
	  
8	  
5	  
	   Resisting:	  	  
a. Entering	  new	  market	  could	  lead	  to	  losses	  
b. Investors	  pull	  out	  due	  to	  risk	  
	  
8	  
4	  
	  
5	  
2	  
	  
Source:  
Rowe, Alan J., Mason, Richard O., Dickel, Karl E., Mann, Richard B., and Mockler, Robert J. 
"Stakeholder Analysis." Strategic Management - A Methodological Approach. Fourth 
Edition. Addison-Wesley. New York. Page 141. 1999.  
Seshan, V. Ph.D. "Stakeholder Analysis." Strategic Management Financial Analysis and Cash 
Flow. Thirteenth Edition. Thomson. Mason, OH. CD-ROM. 2012.	   	  
 56 
	  
Exhibit 3.5 21: Roche External Stakeholder Assumption Graph 2014 for Aposecretase, 
CNS Segment Strategy 
By:	  Alexander	  Anderson	  	  
Stakeholders	   Major	  Assumptions	   Importance	   Certainty	  
4.	  Consumers	  /	  
Patients	  
Supporting:	  	  
a. Supporting	  Alzheimer’s	  patients	  will	  
increase	  patient	  reach	  
b. R&D	  is	  leading	  to	  better	  medicines	  and	  
treatments	  
	  
7	  
	  
8	  
	  
2	  
	  
8	  
	   Resisting:	  	  
a. Unwanted	  side	  effects	  	  
b. Drug	  is	  not	  effective	  
	  
8	  
9	  
	  
2	  
2	  
5.	  Government	  
Regulation	  
Supporting:	  	  
a. Value	  promotion	  of	  public	  health	  
b. Ensure	  products	  are	  safe	  and	  reliable	  	  
	  
5	  
8	  
	  
5	  
7	  
	   Resisting:	  	  
a. Long	  process	  to	  get	  drug	  on	  the	  market	  
b. Support	  from	  the	  government	  could	  fade	  	  
	  
6	  
3	  
	  
9	  
2	  
6.	  Suppliers	   Supporting:	  	  
a. Supportive	  suppliers	  
b. Not	  reliant	  on	  any	  one	  supplier	  
	  
7	  
8	  
	  
7	  
7	  
	   Resisting:	  	  
a. Difficult	  to	  keep	  suppliers	  standards	  high	  
b. Suppliers	  may	  leave	  or	  need	  to	  be	  cut	  
	  
4	  
4	  
	  
5	  
6	  
7.	  Competitors	   Supporting:	  	  
a. Unrivaled	  treatment	  
b. Acquisitions	  and	  no	  competition	  
	  
9	  
8	  
	  
9	  
8	  
	   Resisting:	  	  
a. Generics	  will	  be	  looking	  to	  take	  over	  
b. Will	  not	  get	  the	  benefit	  of	  others	  working	  
on	  the	  same	  thing	  
	  
8	  
4	  
	  
9	  
3	  
	  
Source:  
Rowe, Alan J., Mason, Richard O., Dickel, Karl E., Mann, Richard B., and Mockler, Robert J. 
"Stakeholder Analysis." Strategic Management - A Methodological Approach. Fourth 
Edition. Addison-Wesley. New York. Page 141. 1999.  
Seshan, V. Ph.D. "Stakeholder Analysis." Strategic Management Financial Analysis and Cash 
Flow. Thirteenth Edition. Thomson. Mason, OH. CD-ROM. 2012.	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Exhibit 3.5 22: Roche Force Field Analysis 2014 for Aposecretase, CNS Segment Strategy 
By:	  Alexander	  Anderson	  	  
Supporting	   Resisting	  
	   9	   8	   7	   6	   5	   4	   3	   2	   1	   1	   2	   3	   4	   5	   6	   7	   8	   9	   	  
Roche	  Internal	   Stakeholders	  2013	  
1Sa	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   1Ra	  
1Sb	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   1Rb	  
2Sa	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   2Ra	  
2Sb	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   2Rb	  
3Sa	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   3Ra	  
3Sb	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   3Rb	  
Roche	  External	   Stakeholders	  2013	  
4Sa	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   4Ra	  
4Sb	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   4Rb	  
5Sa	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   5Ra	  
5Sb	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   5Rb	  
6Sa	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   6Ra	  
6Sb	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   6Rb	  
7Sa	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   7Ra	  
7Sb	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   7Rb	  
	  
	  
Stakeholder Supporting a Supporting b Resisting a Resisting b 
Management & 
Employees 1Sa 1Sb 1Ra 1Rb 
Research & 
Development 2Sa 2Sb 2Ra 2Rb 
Stockholders 3Sa 3Sb 3Ra 3Rb 
Consumer / 
Patients 4Sa 4Sb 4Ra 4Rb 
Government 
Regulation 5Sa 5Sb 5Ra 5Rb 
Suppliers 6Sa 6Sb 6Ra 6Rb 
Competitors 7Sa 7Sb 7Ra 7Rb 
 
Source:  
Rowe, Alan J., Mason, Richard O., Dickel, Karl E., Mann, Richard B., and Mockler, Robert J. 
"Stakeholder Analysis." Strategic Management - A Methodological Approach. Fourth 
Edition. Addison-Wesley. New York. Page 141. 1999.  
Seshan, V. Ph.D. "Stakeholder Analysis." Strategic Management Financial Analysis and Cash 
Flow. Thirteenth Edition. Thomson. Mason, OH. CD-ROM. 2012.	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Exhibit 3.5 23: Roche Stakeholders Assumption Matrix 2014 for Aposecretase, CNS 
Segment Strategy 
By:	  Alexander	  Anderson	  	  
Certain  
9 
      1Sa 7Ra 7Sa 
       3Sa 2Rb, 
4Sb, 
7Sb 
 
     2Sa  6Sa 2Ra, 
5Rb, 
6Sb 
 
    6Rb      
Knowledge 
About 
Assumptions 
   6Ra 5Sa  2Sb, 
3Sb 
3Ra  
    1Sb 1Ra     
    7Rb      
   1Rb 3Rb   4Sa 4Ra 4Rb 
Uncertain 0 
         
 0 
Unimportant 
  Impact of Strategy   9 
Important 
 
Stakeholder Supporting a Supporting b Resisting a Resisting b 
Management & 
Employees 1Sa 1Sb 1Ra 1Rb 
Research & 
Development 2Sa 2Sb 2Ra 2Rb 
Stockholders 3Sa 3Sb 3Ra 3Rb 
Consumer / 
Patients 4Sa 4Sb 4Ra 4Rb 
Government 
Regulation 5Sa 5Sb 5Ra 5Rb 
Suppliers 6Sa 6Sb 6Ra 6Rb 
Competitors 7Sa 7Sb 7Ra 7Rb 
Source:  
Rowe, Alan J., Mason, Richard O., Dickel, Karl E., Mann, Richard B., and Mockler, Robert J. 
"Stakeholder Analysis." Strategic Management - A Methodological Approach. Fourth 
Edition. Addison-Wesley. New York. Page 141. 1999.  
Seshan, V. Ph.D. "Stakeholder Analysis." Strategic Management Financial Analysis and Cash Flow. Thirteenth 
Edition. Thomson. Mason, OH. CD-ROM. 2012.Edition. Thomson. Mason, OH. CD-ROM. 2012.	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Strategic	  Position	  and	  Action	  Evaluation	  (SPACE)	  Analysis	  
By:	  Kali	  Jelen	  
Introduction	  
By:	  Kali	  Jelen	  
A Strategic Position and Action Evaluation Analysis (SPACE) is a market analysis tool used to 
determine whether Aggressive, Conservative, Defensive, or Competitive strategy is best for a 
given market.68 This is determined by plotting a graphical representation of a given strategy’s 
environmental stability, industry strength, competitive advantage, and financial strength. The Y 
axis holds the environmental stability and financial strength indicators, while the x axis compares 
the competitive advantage and industry strength indicators. Overall, SPACE analysis is visual 
representation of an undertaking’s strategic position in a market.69 
Environmental	  Stability	  
By:	  Kali	  Jelen	  
Environmental stability factors include technology changes, rate of inflation, demand variability, 
price range of competing products, and barriers to entry, competitive pressures, price elasticity of 
demand, and pressures from substitute products.70 This section helps to establish where Roche 
stands in the pharmaceutical industry and specifically in the central nervous system market. The 
pharmaceutical market is well-established and therefore not exceptionally likely to change. 
Major factors to note are the high scores for competition and the low score for technology. The 
pharmaceutical industry is characterized by cut throat competition and a high rate of technology 
turn over. Part of the reason for the large research and development expenditures in this field is 
due to the need to stay relevant against the competition in an ever changing technological market 
place. The environment of the CNS market segment is fairly stable despite the high technology 
turnover rate and the intense competition. 
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Industry	  Strength	  
By:	  Kali	  Jelen	  
Industry Strength factors include growth potential, profit potential, financial stability, 
technological knowhow, resource utilization, capital intensity, ease of entry into market, and 
productivity utilization. This segment of the SPACE Analysis indicates whether or not the 
industry will remain the same or change over time and directly affects sales and thus profits.71 
Industry strength indicates how Roche can expect to perform in this specific portion of the CNS 
market segment. Factors to note are the high ease of entry and capital intensity scores. The 
pharmaceutical industry in general and the CNS market segment in particular require a large 
amount of capital in the form of research and development dollars which create a very difficult 
barrier to entry. Roche, with its extensive war chest, is able to scale the high cost of entry in to 
the CNS market without too much difficulty, however this barrio could potentially block out 
other, smaller competitors, or even some larger competitors who would choose to focus their 
R&D dollars elsewhere. 
Competitive	  Advantage	  
By:	  Kali	  Jelen	  
The factors influencing competitive advantage are market share, product quality, product life 
cycle, product replacement cycle, customer loyalty, competition’s capacity utilization, 
technological knowhow, vertical integration, and speed of new product introductions. This 
section describes how Roche can expect its product to do against its competitors in the 
pharmaceutical industry.72 Additionally it also indicated the likelihood of Roche maintaining its 
competitive advantage in the future. Aposecretase will be the first drug to address the symptoms 
of Alzheimer’s disease, rather than the symptoms. At first this will give Roche a great advantage 
over its competitors. However, Roche is not the only company working on a treatment of this 
type. Roche can expect to have to compete against strong products from rival pharmaceutical 
companies. Factors to pay attention to in this section are the low speed of new product 
introductions and the low customer loyalty scores. It is difficult to get new products to market in 
the pharmaceutical industry due to government regulations requiring extensive clinical trials and 
testing. While this is burdensome for Roche initially, in the long run it will protect their product 
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as every month a competitor is forced to spend in the clinical trial phase is another moth Roche’s 
drug can continue its’ patent life without direct competition. Additionally, in the pharmaceutical 
industry customers are assumed to have little to no brand loyalty. Instead, factors such as price, 
quality, and effectiveness of the product take precedence.  
Financial	  Strength	  
By:	  Kali	  Jelen	  
Financial Strength factors are return on investment, leverage, liquidity, capital required vs. 
capital available, cash flow, ease of exit form market, risk involved in business, economies of 
scale and expenditure, and inventory turnover. This section indicates how well this project is 
doing using standard financial measures.73 While overall the industry is relatively financially 
stable every new project is a fairly large gamble. Roche is one of the most financial stable 
companies in the industry. Factors to particularly note are the high score for capital available vs 
capital required and the low score for ease of exit from market. Roche’s strong financial position 
allows means that the Aposecretase project will be well funded and supported. The capital 
allocation of 4.61 billion dollars will more than meet the required investment for the 
development and launch of this new project. Aposecretase will by no means be underfunded. 
Another factor to note is the extremely low score for exit to market. It will be very difficult and 
costly to exit the CNS market. Equipment and personnel are too specialized to reallocate or sell 
off. Therefore Roche must be certain if undertaking this project to keep up research and 
development expenditures to ensure the longevity of its product. Roche must be ready to pivot 
their product to address increased threat from competition.  
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Exhibit 3.5.24 Roche Strategic Position and Action Evaluation for Aposecretase Environmental Stability 2014 
By: Kali Jelen 
 
Critical Factors: The high barrier to entry in to this market is driven by the rapid rate at which technology evolves. 
 
Comments: Roche should utilize its past research efforts and currently existing facilities to minimize the barriers to entry for 
Aposecretase. 
 
Source: Seshan, V. Ph.D. Strategic Management Financial Analysis and Cash Flow. Eleventh Edition. Cengage. Mason, OH. CD-ROM. 2010.  
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Exhibit 3.5.25 Roche Strategic Position and Action Evaluation for Aposecretase Industry Strength 2014 
By: Kali Jelen 
 
Critical Factors: The pharmaceutical industry is incredibly strong with massive profit potential. However, it is very difficult to enter 
the market due to the massive amount of capital required and to efficiently utilize resources. 
 
Comments: Aposecretase will be Roche’s first Alzheimer’s medication. The cost to enter the market will be very high and the 
Aposecretase project will only be successful if Roche’s maintains or increases its current financial stability and willingness to invest. 
 
Source: Seshan, V. Ph.D. Strategic Management Financial Analysis and Cash Flow. Eleventh Edition. Cengage. Mason, OH. CD-ROM. 2010.  
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Exhibit 3.5.26 Roche Strategic Position and Action Evaluation for Aposecretase Competitive Advantage 2014 
By: Kali Jelen 
 
Critical Factors: Customer loyalty is virtually non-existent in the pharmaceutical industry. The only important factors are the cost and 
effectiveness of products. Furthermore the speed of new product introductions is incredibly slow due to extensive governmental 
regulations requiring multiple rounds of clinical trials and review. 
 
Comments: Roche should expect to have to wait an period of time before releasing Aposecretase to the public in order to satisfy FDA 
regulations. Furthermore Roche should be extra wary of being out engineer by its competitors, as it will never be able to maintain 
customers based on brand loyalty. 
 
Source: Seshan, V. Ph.D. Strategic Management Financial Analysis and Cash Flow. Eleventh Edition. Cengage. Mason, OH. CD-ROM. 2010.  
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Exhibit 3.5.27 Roche Strategic Position and Action Evaluation for Aposecretase Financial Strength 2014 
By: Kali Jelen 
 
Critical Factors: It is incredibly difficult to exit this market due to the extremely specialized equipment and personnel. 
 
Comments: Roche must be sure to maintain high R&D expenditures to ensure that a new patent can be secured when Aposecretase’s 
patent expires in 2034. 
 
Source: Seshan, V. Ph.D. Strategic Management Financial Analysis and Cash Flow. Eleventh Edition. Cengage. Mason, OH. CD-ROM. 2010.
Factors	  Determining	  Financial	  Strength: R C E
Return	  on	  investment Low 0 1 2 3 4 5 6 High 9 0.9 8.1
Leverage Imbalanced 0 1 2 3 4 5 6 Balanced 7 0.7 4.9
Liquidity Imbalanced 0 1 2 3 4 5 6 Solid 6 0.7 4.2
Capital	  required	  versus	  capital	  available High 0 1 2 3 4 5 6 Low 9 0.8 7.2
Cash	  flow Low 0 1 2 3 4 5 6 High 8 0.9 7.2
Ease	  of	  exit	  from	  market Difficult 0 1 2 3 4 5 6 Easy 3 0.7 2.1
Risk	  involved	  in	  business Much 0 1 2 3 4 5 6 Little 8 0.9 7.2
Inventory	  turnover Slow 0 1 2 3 4 5 6 Fast 4 0.2 0.8
Economies	  of	  scale	  and	  experience Low 0 1 2 3 4 5 6 High 7 0.6 4.2
Total:	   45.9
Average	  =	  3.33
R:	  Relative	  Importance	  of	  Factor
C:	  Chance	  of	  sustaining	  importance
E:	  Combined	  Effect	  of	  Factor
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Exhibit 3.5.28 Roche Strategic Position and Action Evaluation for Aposecretase Action 
Evaluation Graph 2014 
By: Kali Jelen 
 
Comments: According to the SPACE analysis Roche should use a competitive approach to 
implement the Aposecretase strategy. The Alzheimer’s market is primed for a new leader. With 
superior technology and strong capital support Roche can easily gain a sizeable share of the 
market. 
 
Source: 
Mann, Richard B. and Seshan, V. Strategy for the 21st Century, Sixth Edition, IBT Global, 2012.                        
Seshan, V., Strategic Management- Financial Analysis and Cash Flow 13th Edition Cengage Learning, South-          
Western Publishing, 2012. 
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